ArQule presents preliminary clinical data for ARQ 087 demonstrating anticancer activity
ArQule announced preliminary data demonstrate evidence of anticancer activity, defined by objective response rate and disease control rate in an ongoing phase 1/2 biomarker driven trial with ARQ 087 in intrahepatic cholangiocarcinoma. Activity was observed in patients with FGFR2 genetic alterations. June 30, 2016